title: Multi-vessel stenting during primary percutaneous coronary intervention for acute myocardial infarction. A single-center experience.
abstract: BACKGROUND
  Recanalization of the culprit lesion is the main goal of primary angioplasty for acute ST-segment elevation myocardial infarction (STEMI). Patients presenting with acute myocardial infarction and multivessel disease are, therefore, usually subjected to staged procedures, with the primary percutaneous coronary intervention (PCI) confined to recanalization of the infarct-related artery (IRA). Theoretically at least, early relief of stenoses of non-infarct-related arteries could promote collateral circulation, which could help to limit the infarct size. However, the safety and feasibility of such an approach has not been adequately established.
  
  
  METHODS
  In this single-center prospective study we examined 73 consecutive patients who had an acute STEMI and at least one or more lesions > or = 70% in a major epicardial vessel other than the infarct-related artery. In the first 28 patients, forming the multi-vessel (MV) PCI group, all lesions were treated during the primary procedure. In the following 45 patients, forming the culprit-only (CO) PCI group, only the culprit lesion was treated during the initial procedure, followed by either planned-staged or ischemia-driven revascularization of the non-culprit lesions. Fluoroscopy time and contrast dye amount were compared between both groups, and patients were followed up for one year for major adverse cardiac events (MACE) and other significant clinical events.
  
  
  RESULTS
  The two groups were well balanced in terms of clinical characteristics, number of diseased vessels and angiographic characteristics of the culprit lesion. In the MV-PCI group, 2.51 lesions per patient were treated using 2.96 +/- 1.34 stents (1.00 lesions and 1.76 +/- 1.17 stents in the CO-PCI group, both p < 0.001). The fluoroscopy time increased from 10.3 (7.2-16.9) min in the CO-PCI group to 12.5 (8.5-19.3) min in the MV-PCI group (p = 0.22), and the amount of contrast used from 200 (180-250) ml to 250 (200-300) ml, respectively (p = 0.16). Peak CK and CK-MB were significantly lower in patients of the MV-PCI group (843 +/- 845 and 135 +/- 125 vs 1652 +/- 1550 and 207 +/- 155 U/l, p < 0.001 and 0.01, respectively). Similar rates of major adverse cardiac events at one year were observed in the two groups (24% and 28% in multi-vessel and culprit treatment groups, p = 0.73). The incidence of new revascularization in both infarct- and non-infarct-related arteries was also similar (24% and 28%, respectively, p = 0.73).
  
  
  CONCLUSIONS
  We may state from this limited experience that a multi-vessel stenting approach for patients with acute STEMI and multi-vessel disease is feasible and probably safe during routine clinical practice. Our data suggest that this approach may help to limit the infarct size. However, larger studies, perhaps using drug-eluting stents, are still needed to further evaluate the safety and efficiency of this procedure, and whether it is associated with a lower need of subsequent revascularization and lower costs.
authors: Herz-Kreislauf-Zentrum, Segeberger Kliniken, GmbH, Am Kurpark 1, 23795, Bad Segeberg, Germany. ahmed.khattab@segebergerkliniken.de
authors: A A
authors: AA
authors: Khattab
authors: M
authors: M
authors: Abdel-Wahab
authors: C
authors: C
authors: Röther
authors: B
authors: B
authors: Liska
authors: R
authors: R
authors: Toelg
authors: G
authors: G
authors: Kassner
authors: V
authors: V
authors: Geist
authors: G
authors: G
authors: Richardt
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D023921:Coronary Stenosis / Q000150:complications / Q000601:surgery*; D005260:Female; D005471:Fluoroscopy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000601:surgery*; D009204:Myocardial Revascularization / Q000379:methods; D011446:Prospective Studies; D015607:Stents / Q000009:adverse effects; D013997:Time Factors
references: Am Heart J. 2007 May;153(5):719-21
references: 17452144
references: Eur Heart J. 2005 Apr;26(8):804-47
references: 15769784
references: Ann Intern Med. 1973 Nov;79(5):720-33
references: 4148053
references: Scand Cardiovasc J. 2007 Jan;41(1):44-50
references: 17365977
references: N Engl J Med. 1980 Oct 16;303(16):897-902
references: 7412821
references: J Am Coll Cardiol. 1988 Mar;11(3):453-63
references: 3278032
references: Am J Cardiol. 2001 Jul 15;88(2):170-3, A6
references: 11448417
references: Am Heart J. 2007 May;153(5):749-54
references: 17452148
references: N Engl J Med. 1999 Dec 23;341(26):1949-56
references: 10607811
references: Am Heart J. 2004 Sep;148(3):493-500
references: 15389238
references: N Engl J Med. 1994 Jun 16;330(24):1724-30
references: 8190135
references: Int J Cardiovasc Intervent. 2004;6(3-4):128-33
references: 16146905
references: Lancet. 2005 Sep 10-16;366(9489):921-9
references: 16154019
references: Clin Res Cardiol. 2007 Feb;96(2):86-93
references: 17180577
references: Am Heart J. 2007 Feb;153(2):231-7
references: 17239681
references: Clin Res Cardiol. 2007 Jun;96(6):375-82
references: 17453137
references: J Am Coll Cardiol. 2006 Jan 3;47(1):e1-121
references: 16386656